Global Myeloproliferative Disorders Drugs Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|骨髓增生性疾病治療藥的全球市場(2020年∼2027年) Global Myeloproliferative Disorders Drugs Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
The Global Myeloproliferative Disorders Drugs Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Myeloproliferative disorders are the disease of blood and bone marrow that have an unknown cause, and there is a wide range of symptoms. Myeloproliferative disorders are generally considered a clonal disorder that begins with one or more changes in the DNA of a single stem cell in the bone marrow. The changes to the hematopoietic stem cell cause the cell to reproduce repeatedly, creating more abnormal stem cells. These will become one or more types of blood cells. These get worst with time as the number of extra blood cells builds up in the bone marrow and bloodstream. Signs of these disorders include fatigue, itchy skin, night sweats, bone pain, fever, weight loss and major complications include Excessive bleeding, which can happen with a minor cut, bruising, or when capillaries break under the skin are blood clots (thrombosis); the disease changing into leukemia. The treatment depends on which myeloproliferative disorder you have. Some of the most common treatments are chemotherapy, surgery, radiation therapy, phlebotomy, stem cell therapy and others.
The global Myeloproliferative Disorders Drugs market growth is driven by the growing incidence of myeloproliferative disorders, Presence of strong pipeline drugs and changing lifestyle, increasing geriatric population are the major factors of the market.
Growing incidence of myeloproliferative disorders, is expected to drive the growth in the forecast period
The most common form of the myeloproliferative disease is chronic myelogenous leukemia (CML). According to the National Cancer Institute, CML is diagnosed in more than 8,000 patients per year in the United States. The incidence of polycythemia vera in the United States is 5 per 1 million per year, and Essential thrombocythemia has an incidence of 1.5 per 100,000. In contrast, myelofibrosis incidence is estimated to be around 0.9 per 100,000 per year. These increase in the number of myeloproliferative disorders cases will add to the overall global myeloproliferative disorders drugs market.
Presence of strong pipeline drugs, is expected to drive the growth in the forecast period
AbbVie conducting a Phase 1 clinical trial to Evaluate the Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy in Combination with Ruxolitinib and Celecoxib in treating Myeloproliferative disorder patients is expected to complete by 2023, which will increase the demand for the Myeloproliferative disorder drugs market in the forecast period.
Celgene Corporation: A Phase 3, Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions is expected to complete by 2025, which will increase the demand for the Myeloproliferative disorder drugs market in the forecast period.
High Cost of Treatment and Drugs is likely to hamper the global myeloproliferative disease drugs market.
According to the study presented in the American Society of Hematology, annual medical and drug costs for patients with myelofibrosis neoplasms were 2 to 6 times that of patients with ailments other than cancer. For patients with myelofibrosis, the mean total annual costs were $34,690, with outpatient costs accounting for 53% of the total (mean, $18,395). Inpatient visits (23%, $8106), drug costs (22%, $7803), and emergency department visits (1%, $386) accounted for the remaining costs. Patients with myelofibrosis incurred the greatest costs, followed by patients with essential thrombocythemia (mean annual total, $19,672) and polycythemia vera (mean annual total, $11,927).
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global myeloproliferative disorders drugs market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Based on the Drug Type, the global Myeloproliferative Disorders drugs market is segmented into JAK1/JAK2 inhibitor, Anti-Neoplastics, Demethylation Agents, Imatinib mesylate and Others
JAK1/JAK2 inhibitor & Imatinib mesylate segments accounts the largest share in the market.
Imatinib mesylate (Gleevec), protein-tyrosine kinase inhibitor (TKI), manufactured by Novartis Pharmaceuticals Corp, is FDA approved drug in 2001 for use in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in the chronic phase. It binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene and receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML.
Ruxolitinib is a type of targeted cancer drug called a cancer growth blocker. A cancer growth blocker blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene that is important in the production of blood cells. This gene is called JAK2. In December 2014, the US Food and Drug Administration (FDA) expanded the approval of the JAK1/JAK2 inhibitor, ruxolitinib (Jakafi), for the treatment of Polycythemia vera in patients. In November 2011, the JAK1/JAK2 inhibitor, ruxolitinib (Jakafi), manufactured by Incyte Corporation, became the first US Food and Drug Administration (FDA)-approved drug for intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
Based on Distribution channel, the hospital pharmacies are expected to dominate the Global Myeloproliferative Disorders Drugs market during the forecast period
The hospital pharmacies held the largest share in the global Myeloproliferative Disorders drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.Also the medications can be administrated by intravenously under supervision of medical practioners at these locations.
North America region holds the largest market share global Myeloproliferative Disorders Drugs market
North America holds the largest market in the global Myeloproliferative Disorders Drugs market due to the high incidence of cancer, according to the American cancer society, there are about 800 new cases of neuroblastoma each year in the United States. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of orphan drugs for the treatment of neuroblastoma and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Chia Tai Tianqing Pharmaceutical Group Co., Ltd Conducting Phase I Study of TQ05105 Tablets in Subjects with Myeloproliferative Neoplasms.
The Global Myeloproliferative Disorders Drugs Market is quite competitive with some key competitors like Novartis AG, Eli Lilly and Company, Incyte Corporation, Epizyme, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Takeda Pharmaceuticals Company Limited, Apotex Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, M.D. Anderson Cancer Center in Collaboration with Incyte Corporation Evaluating the Ruxolitinib and Lenalidomide Combination as a Therapy for Patients with Myelofibrosis is under Phase 2 clinical trials.
Company Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. It is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). It has 110,000 (2020) total employees and generates $48.66 billion (2020) revenue.
Product Portfolio: The company portfolio includes Oncology, Cardiovascular, Renal and Metabolic Medicine, Immunology, Dermatology, Ophthalmology, Neuroscience, Respiratory and Others.
Novartis - ABL001 (asciminib), a BCR-ABL inhibitor, is under Phase 3 clinical trials in Chronic myeloid leukemia (CML) patients.
The global Myeloproliferative Disorders drugs report would provide an access to an approx. 53 market data table, 45 figures and 240 pages.
LIST NOT EXHAUSTIVE